Galmed (GLMD) announced the grant of a new patent related to its lead compound, Aramchol. The patent covers the use of a combination therapy of Aramchol and Resmetirom for the treatment of non-alcoholic steatohepatitis or NASH and liver fibrosis. With this latest patent, Galmed is strengthening and extending Aramchol’s patent protection through September 2039, securing long-term market exclusivity for its novel NASH therapy. According to consulting firm Research Nester, the global NASH treatment market is projected to grow from about $5.2B in 2022 to over $48B by 2035.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GLMD: